CareDx

CareDx, Inc. was founded in 2000 and is a molecular diagnostics company headquartered in Brisbane, California, USA. CareDx applies modern genomics technology to the development of molecular diagnostic assays, translating patients' immune statuses into clinically actionable information.CareDx has one marketed product, the AlloMap Molecular Expression Testing. The proprietary molecular expression technology used by CareDx to develop the AlloMap test for managing heart transplant patients may also be applicable to post-transplant management for other organ recipients. It is also exploring the application of gene expression testing to other diseases involving immune system activity, such as autoimmune and chronic inflammatory diseases.